Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ: NVAX )

7.275 -0.195 (-2.61%)
Streaming Delayed Price Updated: 9:40 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
Exposures COVID-19 Product Safety
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data. 
Via Stocktwits
Topics Government
Exposures COVID-19 Political Product Safety
Earnings Scheduled For February 27, 2025
Via Benzinga
(NVAX) - Analyzing Novavax's Short Interest
Via Benzinga
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study. 
Via Benzinga
Exposures COVID-19
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling
Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval. 
Via Stocktwits
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
2 Beaten-Down Stocks That Still Aren't Worth Buying
Via The Motley Fool
Topics Cannabis Government Law Enforcement
Exposures Cannabis Legal Political
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities. 
Via Benzinga
Topics World Trade
Exposures Product Safety Tariff
Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful
Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall... 
Via Stocktwits
Exposures COVID-19 Product Safety
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline. 
Via Benzinga
Exposures COVID-19 Product Safety
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration. 
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
Exposures Product Safety
Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?
Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi. 
Via Benzinga
Topics Government
Exposures Political
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Via The Motley Fool
Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?
Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA) 
Via Benzinga
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Via The Motley Fool
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership
The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025. 
Via Stocktwits
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue. 
Via Benzinga
Exposures COVID-19
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples
Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax. 
Via Stocktwits
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch
A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye." 
Via Benzinga
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald... 
Via Benzinga
Topics Government
Exposures Political
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
Exposures COVID-19
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads
As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop. 
Via Benzinga
Topics Government
Exposures Political
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. 
Via Benzinga
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Exposures Political
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing
The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours. 
Via Benzinga
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.